Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385785895> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4385785895 endingPage "27" @default.
- W4385785895 startingPage "20" @default.
- W4385785895 abstract "Evidence that tumor necrosis factor-α (TNF-α) inhibitors may benefit patients with cardiac sarcoidosis (CS) is limited to small case series and both imaging and clinical outcomes in this population are not well known. This study aimed to evaluate the disease course of patients with CS treated with either infliximab or adalimumab therapy based on serial 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and clinical outcomes. An institutional CS research database was queried for patients treated with TNF-α inhibitors between 2016 and 2021. Outcomes included (1) change in mean prednisone dose, (2) FDG-PET improvement, and (3) unplanned hospitalizations, advanced heart failure therapies, or death. Our query yielded 31 patients with CS. A total of 13 patients were on infliximab, 15 patients were on adalimumab, and 3 patients were on adalimumab before transitioning to infliximab. Mean prednisone dose decreased between FDG-PET immediately preceding TNF-α and second after TNF-α FDG-PET (18.6 ± 15.7 mg to 7.7 ± 12.4 mg, p = 0.018). A significant decrease was seen in the mean number of segments demonstrating FDG uptake between most recent pre-TNF-α and first after TNF-α inhibitor FDG-PET (mean segments = 4.2 vs 3.1, p = 0.048). Between earliest pre-TNF-α and first after TNF-α FDG-PET there was a numerical decrease in average myocardial maximum standard uptake values (SUVmax) (4.4 vs 3.1, p = 0.18), and the ratio of SUVmax myocardium:SUVmax blood pool (1.9 vs 1.5, p = 0.26). Within 36 months of initiating TNF-α inhibitor, 4 patients (13%) experienced unplanned cardiovascular hospitalization (median time to hospitalization = 12.1 months). In conclusion, in patients with CS, TNF-α inhibitor therapy is associated with decreased glucocorticoid use, numerical decrease in cardiac FDG uptake, and minimal cardiac morbidity." @default.
- W4385785895 created "2023-08-13" @default.
- W4385785895 creator A5004961625 @default.
- W4385785895 creator A5016991601 @default.
- W4385785895 creator A5019174650 @default.
- W4385785895 creator A5031481195 @default.
- W4385785895 creator A5040073310 @default.
- W4385785895 creator A5040584995 @default.
- W4385785895 creator A5044588325 @default.
- W4385785895 creator A5068227868 @default.
- W4385785895 creator A5079553105 @default.
- W4385785895 date "2023-10-01" @default.
- W4385785895 modified "2023-10-12" @default.
- W4385785895 title "Clinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis" @default.
- W4385785895 cites W1943494332 @default.
- W4385785895 cites W1963628564 @default.
- W4385785895 cites W1979420668 @default.
- W4385785895 cites W2004152794 @default.
- W4385785895 cites W2017769012 @default.
- W4385785895 cites W2028719806 @default.
- W4385785895 cites W2041657104 @default.
- W4385785895 cites W2060789691 @default.
- W4385785895 cites W2102980544 @default.
- W4385785895 cites W2147155927 @default.
- W4385785895 cites W2159513257 @default.
- W4385785895 cites W2914705815 @default.
- W4385785895 cites W2969636156 @default.
- W4385785895 cites W2980094499 @default.
- W4385785895 cites W2986050133 @default.
- W4385785895 cites W3082266669 @default.
- W4385785895 cites W3128321562 @default.
- W4385785895 cites W3134618687 @default.
- W4385785895 cites W3154498073 @default.
- W4385785895 cites W3169337886 @default.
- W4385785895 cites W3200461991 @default.
- W4385785895 cites W4211032738 @default.
- W4385785895 doi "https://doi.org/10.1016/j.amjcard.2023.07.139" @default.
- W4385785895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37579656" @default.
- W4385785895 hasPublicationYear "2023" @default.
- W4385785895 type Work @default.
- W4385785895 citedByCount "0" @default.
- W4385785895 crossrefType "journal-article" @default.
- W4385785895 hasAuthorship W4385785895A5004961625 @default.
- W4385785895 hasAuthorship W4385785895A5016991601 @default.
- W4385785895 hasAuthorship W4385785895A5019174650 @default.
- W4385785895 hasAuthorship W4385785895A5031481195 @default.
- W4385785895 hasAuthorship W4385785895A5040073310 @default.
- W4385785895 hasAuthorship W4385785895A5040584995 @default.
- W4385785895 hasAuthorship W4385785895A5044588325 @default.
- W4385785895 hasAuthorship W4385785895A5068227868 @default.
- W4385785895 hasAuthorship W4385785895A5079553105 @default.
- W4385785895 hasConcept C126322002 @default.
- W4385785895 hasConcept C164705383 @default.
- W4385785895 hasConcept C17991360 @default.
- W4385785895 hasConcept C2775842073 @default.
- W4385785895 hasConcept C2777138892 @default.
- W4385785895 hasConcept C2778198053 @default.
- W4385785895 hasConcept C2778720950 @default.
- W4385785895 hasConcept C2780132546 @default.
- W4385785895 hasConcept C2781301800 @default.
- W4385785895 hasConcept C2989005 @default.
- W4385785895 hasConcept C503630168 @default.
- W4385785895 hasConcept C71924100 @default.
- W4385785895 hasConceptScore W4385785895C126322002 @default.
- W4385785895 hasConceptScore W4385785895C164705383 @default.
- W4385785895 hasConceptScore W4385785895C17991360 @default.
- W4385785895 hasConceptScore W4385785895C2775842073 @default.
- W4385785895 hasConceptScore W4385785895C2777138892 @default.
- W4385785895 hasConceptScore W4385785895C2778198053 @default.
- W4385785895 hasConceptScore W4385785895C2778720950 @default.
- W4385785895 hasConceptScore W4385785895C2780132546 @default.
- W4385785895 hasConceptScore W4385785895C2781301800 @default.
- W4385785895 hasConceptScore W4385785895C2989005 @default.
- W4385785895 hasConceptScore W4385785895C503630168 @default.
- W4385785895 hasConceptScore W4385785895C71924100 @default.
- W4385785895 hasFunder F4320310588 @default.
- W4385785895 hasLocation W43857858951 @default.
- W4385785895 hasLocation W43857858952 @default.
- W4385785895 hasOpenAccess W4385785895 @default.
- W4385785895 hasPrimaryLocation W43857858951 @default.
- W4385785895 hasRelatedWork W1588288904 @default.
- W4385785895 hasRelatedWork W1979155011 @default.
- W4385785895 hasRelatedWork W2052175477 @default.
- W4385785895 hasRelatedWork W2111533060 @default.
- W4385785895 hasRelatedWork W2552612566 @default.
- W4385785895 hasRelatedWork W2566490068 @default.
- W4385785895 hasRelatedWork W2755604283 @default.
- W4385785895 hasRelatedWork W3000540054 @default.
- W4385785895 hasRelatedWork W3149869290 @default.
- W4385785895 hasRelatedWork W4293536498 @default.
- W4385785895 hasVolume "205" @default.
- W4385785895 isParatext "false" @default.
- W4385785895 isRetracted "false" @default.
- W4385785895 workType "article" @default.